Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised controlled trial of longer-term clinical outcomes and cost-effectiveness of standard and new antiepileptic drugs

Next Previous
X
Search
Trial Profile

A randomised controlled trial of longer-term clinical outcomes and cost-effectiveness of standard and new antiepileptic drugs

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbamazepine (Primary) ; Gabapentin (Primary) ; Lamotrigine (Primary) ; Oxcarbazepine (Primary) ; Topiramate (Primary) ; Valproic acid (Primary)
  • Indications Epilepsy; Partial epilepsies
  • Focus Therapeutic Use
  • Acronyms SANAD

    • Most Recent Events

    • 29 Aug 2009 Actual number of patients changed from 2437 to 3000.
    • 24 Mar 2007 Results have been published.
    • 15 Jul 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top